Bevacizumab – popularly marketed as Avastin® – was the first USFDA-approved biological therapy designed to inhibit the formation of new blood vessels in tumors (angiogenesis inhibitor).
The bevacizumab-chemotherapy combination has been found to survival in patients with metastatic colorectal and non–small-cell lung cancer, though previous studies have suggested that patients on this combo treatment are at an increased for arterial blood clots.
But now, treatment with chemotherapy and bavacizumab has been found to be associated with a greater risk of blood clots in patients’ arteries compared to treatment with bevacizumab alone.
As published online on August 7 in the Journal of the National …read more